혈장 분획 시장 예측(-2031년) : 제품, 용도, 요법, 지역별

The plasma fractionation market is expected to reach USD 52.58 billion in 2031, up from USD 36.44 billion in 2026, at a CAGR of 7.6% over the forecast period. The market is primarily driven by rising demand for immunoglobulins across immunology and neurology, strategic expansion of plasma collection capacity by market players, and greater use of plasma-derived therapies. Immunoglobulins, including IVIG and SCIG, are widely used to manage primary immunodeficiencies, autoimmune disorders, and neurological conditions, supporting sustained demand for plasma-derived products. In addition, companies are expanding plasma collection networks and investing in fractionation and manufacturing facilities to secure the source-plasma supply and increase production capacity.

Advances in plasma collection, fractionation, chromatography, and downstream purification are improving plasma utilization and the recovery of therapeutic proteins, including immunoglobulins, albumin, and coagulation factors. However, market growth remains constrained by high treatment costs and reimbursement constraints for plasma-derived products, particularly for long-term therapies requiring repeated administration. Differences in healthcare coverage, reimbursement policies, and patient affordability across countries can limit access to plasma-derived therapies, affecting adoption and creating challenges for market expansion while maintaining product quality, safety, and supply continuity.

"Immunoglobulins segment holds the largest share of the market"

The immunoglobulins segment accounts for the largest share of the plasma fractionation market, driven by the increasing use of IVIG, SCIG, and other immunoglobulins to manage primary immunodeficiencies, autoimmune disorders, and neurological conditions. Immunoglobulins play a critical role in immunology and neurology, and recurring treatment needs support sustained demand for plasma-derived products. The growing prevalence of immune-mediated diseases, rising clinical adoption of immunoglobulin therapies, and continued investments in plasma collection and fractionation capacity are expected to further strengthen this segment's position.

"Therapeutics segment holds the largest share of the market"

The therapeutics segment accounts for the largest share of the plasma fractionation market, driven by the widespread clinical use of plasma-derived medicinal products across immunology, neurology, hematology, critical care, and pulmonology. Therapeutic applications are critical to treating immunodeficiencies, autoimmune and neurological disorders, bleeding disorders, and other conditions requiring plasma-derived therapies. Growing demand for immunoglobulins, coagulation factor concentrates, albumin, and protease inhibitors, along with rising healthcare utilization and investments in plasma-derived product manufacturing, continues to strengthen this segment's position.

"US is expected to grow at the highest CAGR during the forecast period"

The US is expected to post the highest CAGR in the plasma fractionation market, driven by a strong plasma collection infrastructure, an established presence of leading plasma fractionation companies, and high utilization of plasma-derived therapies. Rising demand for immunoglobulins, coagulation factor concentrates, albumin, and other plasma-derived products across therapeutic applications is supporting market growth. Growing investments in plasma collection capacity, fractionation and manufacturing facilities, and domestic supply capabilities are further strengthening the market. In addition, increasing adoption of advanced fractionation, purification, and high-concentration immunoglobulin formulations is expected to support demand across hospitals, specialty clinics, home care settings, and infusion centers.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side- 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (US), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India) are among the key companies offering plasma fractionation products.

Research Coverage

This research report categorizes the plasma fractionation market by product (Immunoglobulins [IVIG, SCIG, and other Immunoglobulins], Coagulation factor concentrates [Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin complex concentrates, Factor XIII, and other coagulation factor concentrates], albumin, protease inhibitors, and other plasma products), application (therapeutics and academics & preclinical research), therapeutic area (neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications), end user (hospitals & specialty clinics, homecare settings & infusion centers, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report's scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the plasma fractionation market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, key strategies, new product launches, acquisitions, and recent developments related to the plasma fractionation market. This report also includes a competitive analysis of emerging startups in the plasma fractionation industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Growing demand for immunoglobulins across immunology and neurology, Strategic expansion of plasma collection capacity by market players, Growing prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency, Increasing utilization of albumin in critical care), restraints (High treatment costs and reimbursement constraints for plasma-derived products, Market disruption caused by recombinant alternatives), opportunities (Government strategies for increasing regional self-sufficiency in plasma fractionation), and challenges (Stringent government regulations for maintaining safety and quality of plasma-derived products) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and innovations in the plasma fractionation market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (USA), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India) among others, in the plasma fractionation market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN PLASMA FRACTIONATION MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 PLASMA FRACTIONATION MARKET OVERVIEW
• 3.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION
• 3.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 PLASMA FRACTIONATION MARKET SHARE, BY PRODUCT, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing demand for immunoglobulins across immunology and neurology
    • 4.2.1.2 Strategic expansion of plasma collection capacity by market players
      • 4.2.1.2.1 Plasma collection-by volume
        • 4.2.1.2.1.1 US
        • 4.2.1.2.1.2 Canada
        • 4.2.1.2.1.3 United Kingdom
        • 4.2.1.2.1.4 Japan
        • 4.2.1.2.1.5 India
        • 4.2.1.2.1.6 Brazil
    • 4.2.1.3 Growing prevalence of respiratory diseases and alpha-

1 antitrypsin deficiency

• 4.2.1.4 Increasing utilization of albumin in critical care
• 4.2.2 RESTRAINTS
  • 4.2.2.1 High treatment costs and reimbursement constraints for plasma-derived products
  • 4.2.2.2 Market disruption caused by recombinant alternatives
• 4.2.3 OPPORTUNITIES
  • 4.2.3.1 Government strategies for increasing regional self-sufficiency in plasma fractionation
• 4.2.4 CHALLENGES
  • 4.2.4.1 Stringent government regulations for maintaining safety and quality of plasma-derived products
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL BIOPHARMA INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025
  • 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 3002.12)
  • 5.6.2 EXPORT SCENARIO (HS CODE 3002.12)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 UK APPROVES DOMESTIC PLASMA FOR FIVE ADDITIONAL PDMPS
  • 5.10.2 TAKEDA'S INDONESIA COLLABORATION STRENGTHENS NATIONAL PDMP ECOSYSTEM
  • 5.10.3 ADVANCED VIRAL INACTIVATION IMPROVES PLASMA-DERIVED PRODUCT MANUFACTURING
• 5.11 IMPACT OF 2025 US TARIFFS ON PLASMA FRACTIONATION MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Hospitals & specialty clinics
    • 5.11.5.2 Homecare settings & infusion centers
    • 5.11.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Cohn's cold ethanol plasma fractionation
    • 6.1.1.2 Plasma fractionation by chromatography
    • 6.1.1.3 Plasma separation by centrifugation
    • 6.1.1.4 Plasma separation by depth filtration
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Facilitated subcutaneous infusion systems
    • 6.1.2.2 Liquid-stable high-concentration (20%) formulations
    • 6.1.2.3 Single-use bioprocessing & continuous chromatography
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 AI-driven analytics & smart fractionation yield optimization
    • 6.1.3.2 Next-generation automated plasmapheresis & smart donor center systems
• 6.2 TECHNOLOGY ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 METHODOLOGY
  • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 6.3.3 LIST OF KEY PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
  • 6.5.1 TOP USE CASES & MARKET POTENTIAL
  • 6.5.2 BEST PRACTICES IN AI-ENABLED PLASMA FRACTIONATION WORKFLOWS
  • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
  • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 PLASMA FRACTIONATION MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 IMMUNOGLOBULINS
  • 9.2.1 IVIG
    • 9.2.1.1 Expanding clinical indications, rising immune disorder diagnoses, and advances in IVIG formulations to drive market growth
  • 9.2.2 SCIG
    • 9.2.2.1 Rising preference for home-based treatment, expanding neurological indications, and patient-friendly administration to drive SCIG demand
  • 9.2.3 OTHER IMMUNOGLOBULINS
• 9.3 COAGULATION FACTOR CONCENTRATES
  • 9.3.1 FACTOR VIII
    • 9.3.1.1 Improved hemophilia diagnosis and reliable plasma-derived product supply to boost demand for Factor VIII
  • 9.3.2 FACTOR IX
    • 9.3.2.1 Hemophilia B diagnosis and continued demand for replacement therapy to support Factor IX utilization
  • 9.3.3 VON WILLEBRAND FACTOR
    • 9.3.3.1 Expanded pediatric prophylaxis and increasing access to specialized bleeding disorder care to support market growth
  • 9.3.4 PROTHROMBIN COMPLEX CONCENTRATES (PCC)
    • 9.3.4.1 Rapid anticoagulation reversal and rising emergency-care requirements to aid market growth
  • 9.3.5 FIBRINOGEN CONCENTRATES
    • 9.3.5.1 Rising demand for targeted coagulation replacement to drive global market growth
  • 9.3.6 FACTOR XIII
    • 9.3.6.1 Growing demand for preventive replacement therapy to support market growth
  • 9.3.7 OTHER COAGULATION FACTOR CONCENTRATES
• 9.4 ALBUMIN
  • 9.4.1 RISING DEMAND FOR CRITICAL CARE AND LIVER DISEASE THERAPIES TO BOOST MARKET GROWTH
• 9.5 PROTEASE INHIBITORS
  • 9.5.1 INCREASING AATD DIAGNOSIS AND DEMAND FOR LONG-TERM AUGMENTATION THERAPY TO PROPEL MARKET
• 9.6 OTHER PLASMA PRODUCTS

10 PLASMA FRACTIONATION MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 THERAPEUTICS
  • 10.2.1 STRONG CLINICAL DEMAND FOR PLASMA-DERIVED THERAPIES TO SUSTAIN THERAPEUTICS AS CORE APPLICATION OF PLASMA FRACTIONATION MARKET
• 10.3 ACADEMICS & PRECLINICAL RESEARCH
  • 10.3.1 EXPANDING USE OF HUMAN PLASMA FRACTIONS IN RESEARCH AND BIOPROCESSING TO SUPPORT DEMAND

11 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA

• 11.1 INTRODUCTION
• 11.2 NEUROLOGY
  • 11.2.1 GROWING UTILIZATION OF PLASMA-DERIVED IMMUNOGLOBULINS IN NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR PLASMA FRACTIONATION
• 11.3 IMMUNOLOGY
  • 11.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCIES AND AUTOIMMUNE DISORDERS TO DRIVE DEMAND FOR PLASMA-DERIVED IMMUNOGLOBULINS
• 11.4 HEMATOLOGY
  • 11.4.1 RISING DEMAND FOR PLASMA-DERIVED COAGULATION FACTORS TO SUPPORT TREATMENT OF BLEEDING DISORDERS
• 11.5 CRITICAL CARE
  • 11.5.1 ESSENTIAL DEMAND FOR ALBUMIN EXPANDERS AND FOUR-FACTOR CONCENTRATE REVERSAL AGENTS TO DRIVE CLINICAL UTILITY IN EMERGENCY SETTINGS
• 11.6 PULMONOLOGY
  • 11.6.1 GROWING DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY TO SUPPORT DEMAND FOR PLASMA-DERIVED PROTEASE INHIBITORS
• 11.7 HEMATO-ONCOLOGY
  • 11.7.1 INCREASING SUPPORTIVE-CARE REQUIREMENTS IN HEMATOLOGICAL MALIGNANCIES TO SUPPORT UTILIZATION OF PLASMA-DERIVED PRODUCTS
• 11.8 RHEUMATOLOGY
  • 11.8.1 EXPANDING USE OF IMMUNOGLOBULIN THERAPY IN IMMUNE-MEDIATED DISORDERS TO SUPPORT DEMAND FOR PLASMA-DERIVED PRODUCTS
• 11.9 OTHER THERAPEUTIC AREAS

12 PLASMA FRACTIONATION MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOSPITALS & SPECIALTY CLINICS
  • 12.2.1 INCREASING UTILIZATION OF PLASMA-DERIVED THERAPIES ACROSS CLINICAL TREATMENT SETTINGS TO DRIVE DEMAND FOR PLASMA FRACTIONATION PRODUCTS
• 12.3 HOME CARE SETTINGS & INFUSION CENTERS
  • 12.3.1 GROWING ADOPTION OF HOME-BASED IMMUNOGLOBULIN ADMINISTRATION TO SUPPORT DEMAND FOR PLASMA-DERIVED THERAPIES
• 12.4 OTHER END USERS

13 PLASMA FRACTIONATION MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Expanding plasma collection, fractionation capacity, and immunoglobulin demand to drive US market growth
  • 13.2.2 CANADA
    • 13.2.2.1 Rising immunoglobulin demand and investments in domestic plasma supply to drive market growth
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Expanding plasma collection infrastructure and rising demand for plasma-derived therapies to drive market growth in Germany
  • 13.3.2 UK
    • 13.3.2.1 Rising immunoglobulin demand, domestic plasma collection, and investments in fractionation capacity to boost market growth
  • 13.3.3 FRANCE
    • 13.3.3.1 Established healthcare infrastructure and public plasma donation model to support access to treatment
  • 13.3.4 ITALY
    • 13.3.4.1 Growing use of immunoglobulins for neurological and immunological disorders to drive demand
  • 13.3.5 SPAIN
    • 13.3.5.1 Growing utilization of albumin for critical care and coagulation factor concentrates for bleeding disorders to support growth
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Large domestic donor-plasma collection network and manufacturers focused on expanding product availability to drive growth
  • 13.4.2 JAPAN
    • 13.4.2.1 Highly organized blood donation system and national focus on securing plasma for domestic therapeutic requirements to boost market
  • 13.4.3 INDIA
    • 13.4.3.1 Substantial unmet treatment needs and efforts to improve access to quality-assured plasma-derived medicines to drive growth
  • 13.4.4 SOUTH KOREA
    • 13.4.4.1 Domestic manufacturing expertise with investments in storage infrastructure and overseas contract manufacturing to expand market
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 National self-sufficiency policy linking locally collected plasma with domestic manufacturing and patient supply to position Australia as major hub
  • 13.4.6 VIETNAM
    • 13.4.6.1 Improvements in healthcare access and growing awareness of plasma-derived therapies to support demand
  • 13.4.7 MALAYSIA
    • 13.4.7.1 Dependence on imported plasma-derived therapies to increase focus on plasma collection, contract fractionation, and long-term supply agreements
  • 13.4.8 INDONESIA
    • 13.4.8.1 Large patient population and increasing diagnosis of neurological and immunological disorders to support demand for immunoglobulins
  • 13.4.9 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Expanding local processing to create opportunities to improve plasma utilization and strengthen Brazil's biopharmaceutical supply chain
  • 13.5.2 MEXICO
    • 13.5.2.1 Broader national strategy to expand pharmaceutical manufacturing and reduce reliance on imported medicines to drive market
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 GCC COUNTRIES
    • 13.6.1.1 Saudi Arabia
      • 13.6.1.1.1 National objective of achieving self-sufficiency in plasma-derived medicines and reducing dependence on imported therapies to aid growth
    • 13.6.1.2 UAE
      • 13.6.1.2.1 Growing investment in pharmaceutical localization and efforts to strengthen national medicine security to boost growth
    • 13.6.1.3 Rest of GCC Countries
  • 13.6.2 TURKEY
    • 13.6.2.1 Domestic fractionation investment, import substitution, and rising demand for plasma-derived therapies to drive growth
  • 13.6.3 EGYPT
    • 13.6.3.1 Domestic plasma self-sufficiency, expanding collection infrastructure, and investment in local fractionation to fuel market
  • 13.6.4 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 INVESTMENTS IN PLASMA COLLECTION, DOMESTIC MANUFACTURING, AND INTERNATIONAL PARTNERSHIPS TO SUPPORT DEVELOPMENT OF MARKET

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023-2026
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
• 14.3 REVENUE ANALYSIS, 2021-2025
• 14.4 MARKET SHARE ANALYSIS, 2025
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product footprint
    • 14.5.5.4 Therapeutic area footprint
    • 14.5.5.5 Application footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 14.6.5.1 Detailed list of key startup/SME players
    • 14.6.5.2 Competitive benchmarking of startups/SMEs
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 COMPANY VALUATION
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 CSL
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches
      • 15.1.1.3.2 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 GRIFOLS, S.A.
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product launches
      • 15.1.2.3.2 Deals
      • 15.1.2.3.3 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 OCTAPHARMA AG
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches
      • 15.1.4.3.2 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 KEDRION S.P.A.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches
      • 15.1.5.3.2 Deals
      • 15.1.5.3.3 Expansions
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 LFB
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Expansions
  • 15.1.7 ADMA BIOLOGICS, INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
  • 15.1.8 SANQUIN
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Expansions
  • 15.1.9 TAIBANG BIOLOGICAL GROUP CO., LTD.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Expansions
  • 15.1.10 GC BIOPHARMA CORPORATE
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches
      • 15.1.10.3.2 Deals
      • 15.1.10.3.3 Expansions
  • 15.1.11 HUALAN BIOLOGICAL ENGINEERING INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
  • 15.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches
      • 15.1.12.3.2 Expansions
  • 15.1.13 EMERGENT
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
  • 15.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Deals
  • 15.1.15 INTAS PHARMACEUTICALS LTD.
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Deals
      • 15.1.15.3.2 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 BHARAT SERUMS AND VACCINES LIMITED
  • 15.2.2 SK PLASMA
  • 15.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
  • 15.2.4 KAMADA PHARMACEUTICALS
  • 15.2.5 CENTURION
  • 15.2.6 PLASMAGEN BIOSCIENCES PVT. LTD.
  • 15.2.7 VIRCHOW BIOTECH
  • 15.2.8 FUSION HEALTHCARE
  • 15.2.9 ICHOR

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Key primary participants
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Key industry insights
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
  • 16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 16.3 MARKET GROWTH RATE PROJECTIONS
• 16.4 DATA TRIANGULATION
• 16.5 FACTOR ANALYSIS
• 16.6 RESEARCH ASSUMPTIONS
• 16.7 RESEARCH LIMITATIONS & RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS